Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TGM1 | P22735 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621378 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2621382 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL70761 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2621342 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2621369 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2999166 | 0.94 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5747781 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5747776 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5747789 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL603957 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119317623-A | Tricyclic quinolone BCL6 bifunctional degradation agents | 树线生物科学公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119019369-A | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115397821-B | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| US-5747522-A | ANTICOAGULANTS; ANTIINFLAMMATORY AGENTS; ANTITUMOR AGENTS | HOFFMAN-LA ROCHE INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5670515-A | TREATMENT OF THROMBOSIS, STROKE, CARDIAC INFARCT, INFLAMMATION, AND ARTERIOSCLEROSIS; ANTITUMOR AGENTS, WOUND HEALING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5658928-A | ANTICOAGULANTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS,WOUND HEALING AGENTS, OSTEOPOROSIS | HOFFMANN-LA ROCHE INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5545658-A | FOR TREATMENT OR PROPHYLAXIS OF ILLNESSES WHICH ARE CAUSED BY THE BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELETS AND BY BLOOD PLATELET AGGREGATION AND CELL-CELL ADHESION | HOFFMAN-LA ROCHE INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0505868-B1 | N-Acyl-alpha-aminoacids derivatives | HOFFMANN LA ROCHE (CH) | 1995-09-13 | — | — | EP | disclosed |
| US-5378712-A | Antithrombosis | Hoffmann-La Roche Inc (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0505868-A2 | N-Acyl-alpha-aminoacids derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | SMN1; SMN2 1897/4885NPC1 1672/4885RAB9A 3978/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885 |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 4391/4885NPC1 1612/4885RAB9A 3106/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | SMN1; SMN2 3554/4885NPC1 1659/4885RAB9A 4373/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | SMN1; SMN2 2142/4885NPC1 3368/4885RAB9A 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.